drugset / Trial / NCT05444322
A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This study is designed to explore the safety and tolerability of RD14-01 for patients with relapsed and/or refractory B-cell non-Hodgkin lymphoma. And to evaluate the efficacy and pharmacokinetics of RD14-01 in patients.
Timeline
- Start
- 2022-07-05
- Primary completion
- 2024-07-10
- Completion
- 2025-07-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RD14-01 | Cell therapy | — | Intravenous |